Status:
COMPLETED
Vtama in Psoriasis Patients Being Treated With Biologics.
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
Eligibility Criteria
Inclusion
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Patient with ≥3% BSA
- Patient has been treated with biologic for a minimum of 24 weeks
- Able and willing to give written informed consent prior to performance of any study-related procedures.
Exclusion
- ≤3% BSA
- Patient not receiving biologic agent, or receiving biologic agent \<24weeks
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 18 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06103695
Start Date
February 27 2023
End Date
October 18 2023
Last Update
October 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schweiger Derm Group
East Windsor, New Jersey, United States, 08520